Results 131 to 140 of about 31,995 (218)

Cost-effectiveness analysis of routine pediatric vaccination of 15-valent pneumococcal conjugate vaccine in South Korea. [PDF]

Hum Vaccin Immunother
Choe YJ, Jeon Y, Park J, Kim H, Yang G, Mohanty S, Floros L, Huang M, Chhabra N, Kumari S, Singh J, Sukarom I.   +11 more
europepmc   +1 more source

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants. [PDF]

Pediatr Infect Dis J
Pichon S, Ullery GM, Cousin L, Sadarangani M, Ryu JH, Monfredo C, Mari K, Pandey A, Personnic S, Pouzet C, Manson C, Silhadi W, Minutello AM.   +12 more
europepmc   +1 more source

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8. [PDF]

Clin Infect Dis
Scott PT, Pathirana J, Kato A, Tytus R, Perez CM, Gilchrist NL, Kanou H, Ha Yoo K, Kania G, Nissen M, Russell AF, Fernsler D, Waleed M, Li J, Buchwald UK, Platt HL.   +15 more
europepmc   +1 more source

Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. [PDF]

Open Forum Infect Dis
Ngamprasertchai T, Ruenroengbun N, Kajeekul R.   +2 more
europepmc   +1 more source

Evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine and clinical and demographic characteristics on pneumococcal carriage density in young children in Papua New Guinea, Lao PDR, and Mongolia. [PDF]

BMC Infect Dis
von Mollendorf C, Jagne I, Ashley EA, Blyth CC, Chan J, Ford RL, Mayxay M, Mulholland EK, Mungun T, Narangerel D, Tundev O, Nation ML, Nguyen CD, Ortika BD, Pell CL, Sapura J, Vilivong K, Lai J, Zhang Y, Dance DAB, Pomat WS, Satzke C, Russell FM, PneuCaPTIVE Research Group.   +23 more
europepmc   +1 more source

Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial. [PDF]

N Engl J Med
Gallagher KE, Lucinde R, Bottomley C, Kaniu M, Suaad B, Mutahi M, Mwalekwa L, Ragab S, Twi-Yeboah L, Berkley JA, Hamaluba M, Karani A, Shangala J, Otiende M, Gardiner E, Mugo D, Smith PG, Tabu C, Were F, Goldblatt D, Scott JAG.   +20 more
europepmc   +1 more source

Clinical Features and Outcomes of Pneumococcal Bacteremia in Children With Sickle Cell Disease in the Pneumococcal Conjugate Vaccine Era. [PDF]

Pediatr Blood Cancer
Yee ME, Abel L, Kalmus G, Patel A, Elmontser M, Bakshi N, Wang YF, Gonzalez MD, Adamkiewicz TV, Yildirim I, Lane PA.   +10 more
europepmc   +1 more source

Clinical and evidence-based considerations for choosing a pneumococcal conjugate vaccine in India: A narrative review. [PDF]

Hum Vaccin Immunother
Yewale V, Chatterjee P, Marathe SM, Taur S, Sathyanarayanan S.   +4 more
europepmc   +1 more source

Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial. [PDF]

Lancet Reg Health Southeast Asia
Thuluva S, Matur RV, Gunneri S, Ningaiah S, Yerroju V, Mogulla RR, Dhar C, Thammireddy K, Paliwal P, Kawade A, Nanjappa P, Pramod J, Narang M, Chakravarthy BS, Virupakashappa PM.   +14 more
europepmc   +1 more source

Pneumococcal conjugate vaccine and pneumococcal common protein vaccines

, 2013
Keith P. Klugman, Steven Black, Ron Dagan, Richard Malley, Cynthia G. Whitney   +4 more
openaire   +1 more source